NASDAQ
MCRB

Seres Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Seres Therapeutics Inc Stock Price

Vitals

Today's Low:
$2.9902
Today's High:
$3.135
Open Price:
$3.07
52W Low:
$2.9902
52W High:
$9.49
Prev. Close:
$3.07
Volume:
2500069

Company Statistics

Market Cap.:
$393.59 million
Book Value:
0.177
Revenue TTM:
$130.37 million
Operating Margin TTM:
-113.87%
Gross Profit TTM:
$-165792000
Profit Margin:
-117.68%
Return on Assets TTM:
-27.31%
Return on Equity TTM:
-671.83%

Company Profile

Seres Therapeutics Inc had its IPO on 2015-06-26 under the ticker symbol MCRB.

The company operates in the Healthcare sector and Biotechnology industry. Seres Therapeutics Inc has a staff strength of 431 employees.

Stock update

Shares of Seres Therapeutics Inc opened at $3.07 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.99 - $3.14, and closed at $3.04.

This is a -0.98% slip from the previous day's closing price.

A total volume of 2,500,069 shares were traded at the close of the day’s session.

In the last one week, shares of Seres Therapeutics Inc have slipped by -16.25%.

Seres Therapeutics Inc's Key Ratios

Seres Therapeutics Inc has a market cap of $393.59 million, indicating a price to book ratio of 11.4112 and a price to sales ratio of 53.2409.

In the last 12-months Seres Therapeutics Inc’s revenue was $130.37 million with a gross profit of $-165792000 and an EBITDA of $-142156992. The EBITDA ratio measures Seres Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Seres Therapeutics Inc’s operating margin was -113.87% while its return on assets stood at -27.31% with a return of equity of -671.83%.

In Q2, Seres Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 10300.7%.

Seres Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.11

Its diluted EPS in the last 12-months stands at $-1.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.11. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Seres Therapeutics Inc’s profitability.

Seres Therapeutics Inc stock is trading at a EV to sales ratio of 42.527 and a EV to EBITDA ratio of -2.793. Its price to sales ratio in the trailing 12-months stood at 53.2409.

Seres Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$406.39 million
Total Liabilities
$77.90 million
Operating Cash Flow
$0
Capital Expenditure
$1.23 million
Dividend Payout Ratio
0%

Seres Therapeutics Inc ended 2024 with $406.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $406.39 million while shareholder equity stood at $22.61 million.

Seres Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $77.90 million in other current liabilities, 128000.00 in common stock, $-889133000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $229.52 million and cash and short-term investments were $229.52 million. The company’s total short-term debt was $5,470,000 while long-term debt stood at $100.74 million.

Seres Therapeutics Inc’s total current assets stands at $251.24 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $7.56 million compared to accounts payable of $12.92 million and inventory worth $5.34 million.

In 2024, Seres Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.23 million.

Comparatively, Seres Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$3.04
52-Week High
$9.49
52-Week Low
$2.9902
Analyst Target Price
$9.83

Seres Therapeutics Inc stock is currently trading at $3.04 per share. It touched a 52-week high of $9.49 and a 52-week low of $9.49. Analysts tracking the stock have a 12-month average target price of $9.83.

Its 50-day moving average was $4.12 and 200-day moving average was $5.19 The short ratio stood at 11.23 indicating a short percent outstanding of 0%.

Around 675.1% of the company’s stock are held by insiders while 8044.2% are held by institutions.

Frequently Asked Questions About Seres Therapeutics Inc

The stock symbol (also called stock or share ticker) of Seres Therapeutics Inc is MCRB

The IPO of Seres Therapeutics Inc took place on 2015-06-26

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$2.48
-0.02
-0.8%
$56.85
-0.84
-1.46%
Kose Corp ADR (KSRYY)
$16.04
0.12
+0.75%
$6.54
0.04
+0.69%
$43.67
-4.18
-8.74%
$52.4
-3.97
-7.04%
$753
-40.45
-5.1%
$1250.65
-50.65
-3.89%
Biosyent Inc. (BIOYF)
$5.74
0
0%
$13.33
0.04
+0.3%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Address

200 Sidney Street, Cambridge, MA, United States, 02139